AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Debt Repayment

Cash used to repay borrowings during the period.

AstraZeneca PLCNYSE: AZN

Debt Repayment · Q3 FY2026 · quarter ended Sep 2026

Debt repayment turns positive

Q3 FY2026 debt repayment was $2.08B, compared with -$387.65M a year earlier. Trailing-twelve-month debt repayment was $793.27M. Over 3 fiscal years it compounded at +11.3% a year.

Context

  • Debt repayment amounted to 2.8% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $2.08B or moves back toward the trailing-twelve-month quarterly average of $198.32M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.08B+185.9% QoQ
Last fiscal yearDec 2025
-$1.65B-191.2% YoY
LTMSep 2026
$793.27M+8.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+636.1%——
1 year-191.2%——
3-year CAGR+11.3%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(1.65B) USD
Year-over-year change
-191.2%

Debt Repayment vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.5% is the 8th highest of 10, against a peer median of +121.9%.
  • Debt repayment amounts to 1.3% of revenue for AZN, versus a peer median of 11.1%.
AZN Competitors
Debt Repayment for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 36.44B DKK-8.0%—11.1%
MRKMerck & Co., Inc.LTM Jun 2026$18.64B USD+723.0%—28.1%
NVSNovartis AGLTM Jun 2026$16.59B USD+704.5%—29.8%
LLYEli Lilly and CompanyLTM Jun 2026$15.22B USD+47.0%—19.1%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$6.49B USD+98.1%-0.9%13.2%
PFEPfizer Inc.LTM Jun 2026$1.78B USD+121.9%-72.4%2.8%
AMGNAmgen Inc.LTM Jun 2026$1.32B USD+157.5%—3.5%
AZNAstraZeneca PLCLTM Sep 2026$793.27M USD+8.5%+11.3%1.3%
JNJJohnson & JohnsonLTM Sep 2026$787M USD-108.7%+8.9%0.8%
ABBVAbbVie Inc.LTM Jun 2026$418M USD+130.0%-70.3%0.6%
Peer median (excluding AZN) —+121.9%-35.6%11.1%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265M)2.5B6.9B8.69B10.23B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
Deferred Income Tax(615M)(619M)000
Stock-Based Compensation615M619M579M00
Change in Working Capital2.02B3.76B300M(893M)(1.16B)
Accounts Receivables(961M)(1.35B)(1.43B)(1.62B)0
Inventory1.58B3.94B(669M)(131M)0
Accounts Payables961M1.35B1.43B00
Other Working Capital444M(184M)969M862M(1.16B)
Other Non-Cash Items105M(1.7B)(2.37B)(1B)(220.71M)
Operating Cash Flow5.96B9.81B10.35B11.86B14.58B
Capital Expenditures(2.2B)(2.57B)(3.78B)(4.59B)(5.91B)
Acquisitions (Net)(9.43B)(1.06B)(1.18B)(3.93B)(1.24B)
Purchases of Investments(184M)(159M)(136M)(96M)(229M)
Sales of Investments105M42M129M108M131M
Other Investing Activities654M789M(1.52B)(2.14B)(2.66B)
Investing Cash Flow(11.06B)(2.96B)(4.06B)(7.98B)(6.81B)
Debt Repayment7.89B(1.2B)(965M)1.81B(1.65B)
Common Stock Issued29M29M33M(43M)(481M)
Common Stock Repurchased00000
Dividends Paid(3.86B)(4.36B)(4.48B)(4.63B)(4.97B)
Other Financing Activities(418M)(1.29B)(1.15B)(1.13B)(442M)
Financing Cash Flow3.65B(6.82B)(6.57B)(4B)(7.54B)
Effect of Forex Changes(62M)(80M)(60M)(93M)46M
Net Change in Cash(1.51B)(55M)(346M)(208M)269M
Free Cash Flow3.76B7.24B6.57B7.28B8.67B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.